Drug Profile
Research programme: anti-PDGFR alpha and beta monoclonal antibodies - Eli Lilly and Company
Alternative Names: Anti-PDGFR monoclonal antibodies - Eli Lilly and Company; PDGFRβ MAb - Eli Lilly and CompanyLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ImClone Systems
- Developer Eli Lilly and Company
- Class Monoclonal antibodies
- Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Platelet-derived growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
- 16 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section
- 14 Jun 2005 Preclinical development is ongoing